Trevena's Play Out Of Pain Space Fails In Phase IIb
Trevena Inc.'s future as more than just a one-trick pony is in question following the company's announcement it is discontinuing development of acute heart failure therapy, TRV027, after the drug failed to meet primary or secondary endpoints in a Phase IIb study.
You may also be interested in...
Last week saw the NASDAQ Biotechnology Index (NBI) finish up 2.9%, outperforming a flat week for the broad market S&P 500 index. In the past six months this has been a reasonably rare event although it was often the case in the last biotech bull market that ended last summer. While much of the NBI's performance came from the relief rally on Friday, May 20, some commentators on social media were hailing it as the start of a recovery in biotechnology.
Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – in vitro diagnostics and medical devices – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in September 2021. Data provided by Biomedtracker.
In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2021. Data provided by Biomedtracker.